Tizaro Tirzepatide Injection contains Tirzepatide, a prescription injectable medicine used with diet and exercise to help improve blood glucose control in eligible patients with type 2 diabetes mellitus. The exact strength and presentation should be confirmed on the original product packaging. Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It works by supporting glucose-dependent insulin release, reducing inappropriate glucagon secretion, slowing gastric emptying, and helping regulate appetite. Tizaro Tirzepatide Injection must be used only under the supervision of a qualified healthcare professional. The prescribed strength, dosage-escalation schedule, and treatment duration depend on blood glucose levels, current medicines, treatment response, and individual tolerability.

Key Features

• Contains Tirzepatide: A dual GIP and GLP-1 receptor agonist.
• Supports Blood Glucose Control: Used with diet and exercise for eligible patients with type 2 diabetes.
• Once-Weekly Administration: Administered according to the schedule prescribed by a healthcare professional.
• Subcutaneous Injection: Injected under the skin using the supplied presentation.
• Multiple Strengths: Use only the strength prescribed by your healthcare provider and printed on the original pack.

Active Ingredient

• Tirzepatide: A medicine that activates GIP and GLP-1 receptors to help regulate blood glucose levels in patients with type 2 diabetes.

Uses

• Improvement of blood glucose control in eligible patients with type 2 diabetes mellitus.
• Used together with an appropriate diet, exercise, and diabetes-management plan.
• May be prescribed alone or with other diabetes medicines based on the patient’s clinical requirements.
• Not intended for treating type 1 diabetes or diabetic ketoacidosis.

How to Use

• Use Tizaro Tirzepatide Injection exactly as prescribed by your healthcare provider.
• Administer it as a subcutaneous injection once weekly on the prescribed day.
• It may be administered at any time of the day, with or without meals.
• Inject under the skin of the abdomen, thigh, or upper arm as demonstrated by a healthcare professional.
• Rotate the injection site with each weekly dose.
• Do not inject into a vein or muscle.
• Do not mix tirzepatide with insulin or another injectable medicine in the same syringe.
• Do not change the strength, increase the dose, or stop treatment without medical advice.

Precautions

• Use only with a valid prescription and appropriate medical supervision.
• Inform your doctor if you have pancreatic disease, gallbladder problems, kidney disease, severe digestive problems, or diabetic retinopathy.
• Inform your doctor if you use insulin or sulfonylurea medicines, as the risk of low blood glucose may increase.
• Inform your healthcare provider about all prescription medicines, supplements, vitamins, and herbal products you use.
• Tell your healthcare provider that you use tirzepatide before surgery or a procedure requiring general anaesthesia or deep sedation.
• Do not use during pregnancy unless specifically advised by a qualified healthcare professional.
• Consult your doctor before use while breastfeeding or when planning pregnancy.

Warning

• Thyroid Tumour Risk: Tirzepatide caused thyroid C-cell tumours in animal studies. It is unknown whether this risk applies to humans.
• Do not use if you or a family member has had medullary thyroid carcinoma or if you have Multiple Endocrine Neoplasia syndrome type 2.
• Pancreatitis: Stop treatment and seek medical advice for severe, persistent abdominal pain that may extend to the back.
• Low Blood Glucose: The risk may increase when used with insulin or medicines that stimulate insulin release.
• Dehydration and Kidney Problems: Persistent vomiting or diarrhoea may cause dehydration and affect kidney function.
• Serious allergic reactions, severe gastrointestinal problems, gallbladder disease, or worsening diabetic retinopathy may occur.
• Seek urgent medical assistance for facial swelling, difficulty breathing, severe abdominal pain, persistent vomiting, fainting, or symptoms of severe hypoglycaemia.

Common Side Effects

• Nausea.
• Diarrhoea.
• Reduced appetite.
• Vomiting.
• Constipation.
• Indigestion.
• Stomach or abdominal discomfort.
• Injection-site reactions.

Storage

• Store according to the temperature instructions printed on the original Tizaro packaging.
• Tirzepatide injections are generally stored under refrigeration between 2°C and 8°C.
• Do not freeze or use the injection if it has been frozen.
• Protect the product from excessive heat and direct light.
• Keep it in the original packaging until use.
• Do not use if the solution is discoloured, cloudy, contains particles, or the device is damaged.
• Keep out of reach of children and unauthorized individuals.

Legal Disclaimer: Tizaro Tirzepatide Injection is a prescription medicine intended for use only under the supervision of a qualified healthcare professional. The approved indication, age group, available strengths, and storage conditions may vary by country and product presentation. This information is provided for educational purposes only and should not replace professional medical advice, diagnosis, treatment, the original product label, or the prescribing information supplied with the medicine.

The post Tizaro Tirzepatide Injection appeared first on PMC Herbals.

Mounjaro 15mg KwikPen contains Tirzepatide 15 mg per dose in a 2.4 mL multi-dose pre-filled pen. It is a prescription injectable medicine used under medical supervision to help improve blood sugar control in adults with type 2 diabetes mellitus, along with diet, exercise, and lifestyle management as advised by a healthcare professional. Tirzepatide is a dual GIP and GLP-1 receptor agonist. It works by helping the body release insulin when blood sugar levels are high, reducing excess sugar release from the liver, slowing stomach emptying, and supporting better blood glucose control when used as prescribed. Mounjaro 15mg KwikPen is designed for once-weekly subcutaneous injection. Each pen contains 4 fixed weekly doses, with each dose delivering 15 mg/0.6 mL. This strength should be used only if specifically prescribed by a qualified healthcare professional.

Key Features

• Contains Tirzepatide 15 mg: A dual GIP and GLP-1 receptor agonist used for type 2 diabetes management.
• 2.4 mL Multi-Dose Pen: Contains 4 fixed weekly doses in one pre-filled KwikPen.
• Once-Weekly Use: Designed for one subcutaneous injection per week as prescribed.
• Highest Dose Strength: Used only after proper dose escalation and medical evaluation.
• Prescription-Only Injection: Should be used only under medical supervision.

Active Ingredient

• Tirzepatide 15 mg per 0.6 mL dose: A dual GIP and GLP-1 receptor agonist used to support blood sugar control in adults with type 2 diabetes mellitus.

How to Use

• Use Mounjaro 15mg KwikPen exactly as prescribed by your doctor.
• Inject once weekly under the skin, usually in the abdomen, thigh, or upper arm as advised.
• Use a new pen needle for each injection.
• Do not inject into a vein or muscle.
• Use on the same day each week for better routine adherence.
• Do not share your KwikPen with anyone, even if the needle has been changed.
• After completing 4 doses, dispose of the pen safely as instructed by your healthcare provider.
• Do not change the dose or stop using this medicine without consulting your doctor.

Precautions

• Use only under the supervision of a qualified healthcare professional.
• Inform your doctor if you have pancreas problems, kidney disease, liver disease, stomach emptying problems, gallbladder disease, diabetic eye disease, or any serious medical condition.
• Tell your doctor if you are pregnant, planning a pregnancy, or breastfeeding.
• Inform your healthcare provider about all diabetes medicines, insulin, prescription medicines, OTC products, vitamins, and supplements you are using.
• Monitor blood sugar levels regularly as advised by your doctor.
• This medicine is not intended for type 1 diabetes or diabetic ketoacidosis.

Warning

• Possible side effects may include nausea, vomiting, diarrhea, constipation, stomach pain, reduced appetite, indigestion, bloating, or injection-site reactions.
• Seek medical help immediately if you develop severe abdominal pain, persistent vomiting, dehydration, allergic reaction, swelling, breathing difficulty, or signs of pancreatitis.
• Do not use this medicine if you have a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 unless your doctor confirms it is appropriate.
• The risk of low blood sugar may increase when used with insulin or sulfonylurea medicines.
• This medicine should not be used as a cosmetic weight-loss product.
• Use only as directed by your healthcare provider.

Storage

• Store in a refrigerator as directed on the product label.
• Do not freeze the pen.
• Protect from direct sunlight and excessive heat.
• Keep the pen cap on when not in use.
• Keep out of reach of children and pets.
• Do not use if the solution appears cloudy, discolored, frozen, or contains particles.

Legal Disclaimer: Mounjaro 15mg KwikPen is a prescription injectable medicine and should be used only under the supervision of a qualified healthcare professional. This information is provided for educational and product information purposes only and should not replace professional medical advice, diagnosis, or treatment. Always follow your doctor’s instructions before using this medicine.

The post Mounjaro 15mg KwikPen appeared first on PMC Herbals.

Mounjaro 12.5mg KwikPen contains Tirzepatide 12.5 mg per dose in a multi-dose pre-filled pen. It is a prescription injectable medicine used under medical supervision to help improve blood sugar control in adults with type 2 diabetes mellitus, along with diet, exercise, and lifestyle management as advised by a healthcare professional. Tirzepatide is a dual GIP and GLP-1 receptor agonist. It works by helping the body release insulin when blood sugar levels are high, reducing excess sugar release from the liver, slowing stomach emptying, and supporting better blood glucose control when used as prescribed. Mounjaro 12.5mg KwikPen is designed for once-weekly subcutaneous injection. Each KwikPen contains 4 fixed doses, with one dose taken each week. It should be used only as directed by your doctor, nurse, or trained healthcare professional.

Key Features

• Contains Tirzepatide 12.5 mg: A dual GIP and GLP-1 receptor agonist used for type 2 diabetes management.
• Multi-Dose KwikPen: Contains 4 full weekly doses in one pre-filled pen.
• Once-Weekly Use: Designed for one subcutaneous injection per week as prescribed.
• Supports Blood Sugar Control: Helps improve glycemic control when combined with diet and exercise.
• Prescription-Only Injection: Should be used only under medical supervision.

Active Ingredient

• Tirzepatide 12.5 mg per dose: A dual GIP and GLP-1 receptor agonist used to support blood sugar control in adults with type 2 diabetes mellitus.

How to Use

• Use Mounjaro 12.5mg KwikPen exactly as prescribed by your doctor.
• Inject once weekly under the skin, usually in the abdomen, thigh, or upper arm as advised.
• Use a new pen needle for each injection.
• Do not inject into a vein or muscle.
• Use it on the same day each week for better routine adherence.
• Do not share your KwikPen with anyone, even if the needle has been changed.
• After completing 4 doses, dispose of the pen safely as instructed by your healthcare provider.
• Do not change the dose or stop using this medicine without consulting your doctor.

Precautions

• Use only under the supervision of a qualified healthcare professional.
• Inform your doctor if you have pancreas problems, kidney disease, liver disease, stomach emptying problems, gallbladder disease, diabetic eye disease, or any serious medical condition.
• Tell your doctor if you are pregnant, planning a pregnancy, or breastfeeding.
• Inform your healthcare provider about all diabetes medicines, insulin, prescription medicines, OTC products, vitamins, and supplements you are using.
• Monitor blood sugar levels regularly as advised by your doctor.
• This medicine is not intended for type 1 diabetes or diabetic ketoacidosis.

Warning

• Possible side effects may include nausea, vomiting, diarrhea, constipation, stomach pain, reduced appetite, indigestion, bloating, or injection-site reactions.
• Seek medical help immediately if you develop severe abdominal pain, persistent vomiting, dehydration, allergic reaction, swelling, breathing difficulty, or signs of pancreatitis.
• Do not use this medicine if you have a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 unless your doctor confirms it is appropriate.
• The risk of low blood sugar may increase when used with insulin or sulfonylurea medicines.
• This medicine should not be used as a cosmetic weight-loss product.
• Use only as directed by your healthcare provider.

Storage

• Store in a refrigerator as directed on the product label.
• Do not freeze the pen.
• Protect from direct sunlight and excessive heat.
• Keep the pen cap on when not in use.
• Keep out of reach of children and pets.
• Do not use if the solution appears cloudy, discolored, frozen, or contains particles.

Legal Disclaimer: Mounjaro 12.5mg KwikPen is a prescription injectable medicine and should be used only under the supervision of a qualified healthcare professional. This information is provided for educational and product information purposes only and should not replace professional medical advice, diagnosis, or treatment. Always follow your doctor’s instructions before using this medicine.

The post Mounjaro 12.5mg KwikPen appeared first on PMC Herbals.